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Abstract 1 
Background & Aims: It has been hypothesized that ω-3 polyunsaturated fatty acids 2 
have anti-atherosclerotic and neuronal protective functions and may benefit prevention 3 
of dementia, but the epidemiological evidence, especially for α-linolenic acid, is quite 4 
limited. The aim of this study was to examine whether serum ω-3 polyunsaturated fatty 5 
acids are associated with risk of dementia. 6 
Methods: We performed an intracohort case-control study nested in a 7 
community-based cohort, the Circulatory Risk in the Community Study, involving 8 
7586 Japanese individuals aged 40 to 74 years at the baseline period of 1984 to 1994. 9 
Omega-3 polyunsaturated fatty acid constituents (α-linolenic, eicosapentaenoic, and 10 
docosahexaenoic acids) in serum total lipid were measured in 315 cases of incident 11 
disabling dementia in the above-mentioned cohort between 1999 and 2004, and in 630 12 
controls whose age, sex, area, and baseline year were matched with the cases. 13 
Results: As we had postulated, serum α-linolenic acid was inversely associated with 14 
risk of disabling dementia: the multivariate odds ratios (95% confidence intervals) 15 
were 0.57 (0.39-0.85), 0.51 (0.34-0.76), and 0.61 (0.41-0.90) for persons with the 16 
second, third, and highest quartiles of serum α-linolenic acid, respectively, as 17 
compared with the lowest quartile (P for trend = 0.01). Associations of other ω-3 fatty 18 
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acids with disabling dementia were not statistically significant 19 
Conclusions: Serum α-linolenic acid was inversely associated with risk of disabling 20 
dementia. Although the causality needs to be confirmed by randomized control trials, 21 
we identified serum α-linolenic acid as a biomarker that predicts future dementia. 22 
Keywords: ω-3 (n-3) polyunsaturated fatty acids; cognitive dysfunction; follow-up 23 
study; α-linolenic acid (ALA); eicosapentaenoic acid (EPA); docosahexaenoic acid 24 
(DHA) 25 
26 
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Introduction 27 
Alpha-linolenic acid (ALA), a plant-derived ω-3 polyunsaturated fatty acid, is an 28 
essential fatty acid, with anti-atherosclerotic and neuronal protective functions. Several 29 
studies have reported that long-chain ω-3 polyunsaturated fatty acids of marine origin, 30 
such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may be useful 31 
in preventing dementia.[1-3] ALA, a ω-3 polyunsaturated fatty acid of plant origin, is 32 
also expected to have a similar effect, but such evidence is limited. 33 
 The association between fish and coronary heart disease was non-linear and 34 
had a threshold effect[4], whereas that between dietary ALA intake and coronary heart 35 
disease may be linear [5]. In this context, we hypothesized that serum proportions of 36 
ALA, rather than of other ω-3 fatty acids, are inversely associated with risk of incident 37 
disabling dementia among Japanese individuals, because most Japanese may consume 38 
higher amounts of fish than those recommended for prevention of coronary heart 39 
disease [6], but may not do so for ALA.  40 
41 
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Materials and methods 42 
The Circulatory Risk in Communities Study (CIRCS) is an ongoing dynamic 43 
community-based prospective study involving 5 communities in Japan. Details of the 44 
CIRCS protocol have been described elsewhere.[7] In the present study, we included 2 45 
communities, Ikawa and Kyowa, where disabling dementia surveillance is being 46 
conducted and sera were stored.  47 
 We set the baseline risk set as 7,586 people aged 40 to 74 years living in these 48 
2 communities who participated in annual health checkups in Ikawa from1989 to 1991 49 
and 1995 and in Kyowa from 1984 to 1994 (except for 1988), in which stored sera were 50 
available. Of these, a total of 315 patients were identified who were diagnosed in 51 
Kyowa between 1999 and 2004 and in Ikawa between 1999 and 2013 as having 52 
disabling dementia between 60 and 89 years of age and who participated in annual 53 
health checkups (baseline) at least 5 years before receiving the dementia diagnosis and 54 
provided sera for storage at baseline. 55 
The diagnosis of disabling dementia was performed by attending physicians 56 
under the National Long-Term Care Insurance System (which is a compulsory insurance 57 
for all individuals aged 40 years or over in Japan); the criteria of disabling dementia 58 
were the same as those of our previous study[8], wherein the validation of the criteria 59 
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and the details of the study protocol are also described. As supplemental analysis, we 60 
further classified the dementia cases into cases with and without history of stroke on the 61 
basis of a systematic stroke registration described elsewhere.[7] 62 
In total, 630 randomly selected controls, whose age (± 3 years), sex, area, and 63 
baseline year were matched at a ratio of 2:1 with the cases, were also identified from the 64 
risk set by incident density methods. Venous blood was collected at baseline at the 65 
checkup sites, and sera were prepared from the blood samples as soon as possible 66 
thereafter. The serum samples were collected in 0.3-mL tubes and stored at −80°C until 67 
measurement. The extraction of total lipids and measurements of serum fatty acid 68 
compositions using gas chromatography were described in detail elsewhere.[9] Of the 69 
studied sera, 92% were drawn in the nonfasting state (<8 hours from the last meal). 70 
Potential risk factors for disabling dementia were measured at the baseline 71 
examination at the same time as the blood collection. Well-trained study physicians 72 
measured the arterial systolic and fifth-phase diastolic blood pressures using standard 73 
mercury sphygmomanometers on the right arm of the participants, who were quietly 74 
seated after having rested for at least 5 minutes. If the first systolic blood pressure 75 
reading was ≥140 mmHg and/or the diastolic blood pressure was ≥90 mmHg, the 76 
physicians repeated the measurement. For these cases, the second reading was used in 77 
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the analyses; otherwise, the first reading was used. Height without shoes and weight in 78 
light clothing were measured and body mass index was calculated as weight in 79 
kilograms divided by height in meters squared. Face-to-face interviews were conducted 80 
to determine drinking (non-current or current) and smoking (never, ex, or current) status, 81 
antihypertensive medication, cholesterol-lowering medication, and diabetes medication. 82 
Serum glucose and total cholesterol were measured at baseline without fasting 83 
requirement. Diabetes mellitus was defined as fasting serum glucose ≥ 126 mg/dL or 84 
nonfasting serum glucose ≥ 200 mg/dL, or being under medication for diabetes. 85 
We conducted conditional logistic analyses using SAS 9.1.3. Service Pack 4 86 
(SAS Institute, Cary, NC, USA) with adjustments for age, smoking status, systolic 87 
blood pressure, diabetes mellitus, and use of antihypertensive medication. For the 88 
missing values for these variables (<2% of each variable), we set dummy variables and 89 
included them in the models. All probability values for the statistical tests were 2-tailed, 90 
and probability values below 0.05 were considered significant. Informed consent was 91 
obtained from community leaders and verbally from individual participants according to 92 
the guidelines of the Council for International Organizations of Medical Science[10], 93 
which was common practice at that time in Japan. The study was approved by the 94 
institutional review boards of the Osaka Center for Cancer and Cardiovascular Disease 95 
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Prevention and of the University of Tsukuba. 96 
97 
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Results 98 
Systolic blood pressures and prevalence of diabetes were significantly higher in the 99 
dementia cases than in the non-cases (Table 1). Diastolic blood pressure and prevalence 100 
of current smokers were slightly higher among the cases than among the non-cases. The 101 
mean value of ALA, but not of EPA or DHA, was significantly lower among the cases 102 
than among the non-cases. The other baseline characteristics did not differ materially 103 
between them. As expected, EPA (3.6% total fatty acid) and DHA (5.5% total fatty acid) 104 
were very high among this Japanese population. 105 
 After follow-up (median, 12.5 years and maximum, 23.8 years), we found an 106 
inverse association between serum ALA and the risk of incident dementia (Table 2). The 107 
multivariate odds ratios and 95% confidence intervals for persons with the second, third, 108 
and highest quartiles of ALA were 0.57 (0.39–0.85), 0.51 (0.34–0.76), and 0.61 109 
(0.41–0.90), respectively, compared with the lowest quartile (P for trend = 0.01). As for 110 
EPA and DHA, no associations with incident dementia were observed. 111 
 As supplemental analyses, we classified the dementia cases further into cases 112 
with and without history of stroke, and examined the associations of ALA, EPA and 113 
DHA with them by means of unconditional logistic regression models. The association 114 
of ALA with disabling dementia was generally similar between them: For dementia with 115 
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history of stroke (cases n=110), the multivariate odds ratios and 95% confidence 116 
intervals were 0.62 (0.35–1.11), 0.55 (0.30–1.01), and 0.70 (0.40–1.22) for persons with 117 
the second, third, and highest quartiles of ALA, respectively, as compared with the 118 
lowest quartile (P for trend = 0.20). For dementia without history of stroke (cases 119 
n=205), those were 0.52 (0.33–0.81), 0.48 (0.30–0.75), and 0.55 (0.35–0.85), 120 
respectively (P for trend = 0.009). As for EPA and DHA, no associations with dementia 121 
either with or without of history of stroke, were observed.122 
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Discussion 123 
A strong inverse association between serum ALA proportion and incident disabling 124 
dementia was found in the Japanese population. No such association was found for EPA 125 
or DHA. This is the first prospective study to find an inverse association of serum ALA 126 
with risk of disabling dementia. 127 
 A few animal and human studies supported our finding that ALA may have a 128 
beneficial impact on neural protection. Rats fed a low ALA diet had inferior learning 129 
capacity [11]. Mice fed a high ALA diet had greater learning ability and less hyperactive 130 
behavior than did those fed a low ALA diet.[12] Human erythrocyte ALA, but not EPA 131 
and DHA, was correlated with cognitive decline in a cross-sectional study of 57 Korean 132 
research participants.[13] Another cross-sectional study of 1,299 Italian research 133 
participants showed that those with dementia had lower concentrations of ALA than did 134 
those with no cognitive impairment.[14] The authors of that study did not find a 135 
significant association with EPA or DHA.[14] Concordant with these animal and 136 
cross-sectional studies, the present study first showed that ALA was inversely 137 
associated with risk of dementia in a study with a prospective design and sufficient 138 
sample size. In contrast, 2 prospective studies did not find such an association. One 139 
study examined plasma fatty acid composition and risk of cognitive decline in 2,251 140 
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white research participants (aged 50–65 years) in Minnesota, USA, and found no 141 
association between plasma ALA and cognitive decline in their 9-year follow-up.[15] 142 
Another study involving 1,214 elderly research participants (≥ 65 years) in Bordeaux, 143 
France, also did not find any association of ALA with cognitive decline in their 4-year 144 
follow-up.[16] The reasons for the discrepancy between the findings of these studies 145 
and those of the present study are unknown, but the shorter follow-up (compared with 146 
the 24-year follow-up of the present study) and the smaller number of cases (140 cases 147 
in Minnesota and 65 cases in Bordeaux as compared with the 630 cases of the present 148 
study), as well as differences in ethnicity, settings, age distribution, distribution of ALA, 149 
and endpoint determination across the studies might explain the inconsistent results. 150 
 Diet studies, although showing somewhat weak association, have also reported 151 
generally similar results. The Rotterdam Study showed a non-significant inverse trend 152 
between ALA intake and risk of dementia.[1] Another study, The Chicago Health and 153 
Aging Project, showed that ALA intake was inversely and linearly associated with risk 154 
of Alzheimer disease in age-adjusted models, but not in a multivariate adjusted model 155 
including the APOE ε4 allele.[17] They also found an interaction of the APOE ε4 allele 156 
with ALA intake in relation to Alzheimer disease; that is, the dietary ALA-Alzheimer 157 
disease association was observed only among persons with the APOE ε4 allele. We 158 
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unfortunately do not have APOE ε4 allele information, but the APOE ε4 allele is less 159 
prevalent among Japanese than among white individuals.[18] As for trials, Geleijnse et 160 
al. performed a randomized double-blind placebo-controlled trial among 2911 coronary 161 
patients. The decline in scores of the mini-mental state examination did not differ 162 
significantly between the patients with 2 g/day supplementation of ALA and those 163 
taking the placebo control after a 40-month intervention: the difference, however, was 164 
almost marginally significant (-0.74 versus -0.60 points, p=0.12).[19] Another 165 
randomized double-blind placebo-controlled trial showed that the supplementation of a 166 
mixture of ALA and linolenic acids significantly improved short-term memory in 167 
Alzheimer disease patients after the 4-week intervention.[20] Although their outcomes 168 
were not incident dementia, the findings of those intervention studies were in line with 169 
the present study. 170 
 The nonlinear association between fish and coronary heart disease and its 171 
threshold effect have been well discussed.[4] We hypothesized that the associations of 172 
EPA and DHA with risk of dementia would be weak; ie, the very high consumption of 173 
fish and smaller variation in fish intake in Japanese would cause any associations to be 174 
obscured. Generally, Japanese consume far higher amounts of fish than do western 175 
populations.[21] In fact, in the current study’s population, the EPA and DHA 176 
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proportions were 3.6% and 5.5% of total fatty acid, respectively, which is far higher 177 
than those of Italian subjects: 0.6% for EPA and 2.3% for DHA [14]; the ALA 178 
proportion was also much higher (1.0% in the present study vs 0.4% in the Italian study). 179 
In addition, associations between EPA and DHA intake/supplementation and risk of 180 
dementia in previous intervention trials and cohort studies were undetermined[22-24], 181 
which was in line with our null results for the association between these fatty acids in 182 
serum and risk of dementia. Of note, though we found a statistically significant trend for 183 
linearity, the association between serum ALA and disabling dementia were virtually 184 
nonlinear, which suggested the existence of a threshold effect. 185 
 Several limitations of this study should be noted. First, attending physicians 186 
diagnosed the disabling dementia. However, we should also mention that such diagnosis 187 
by attending physicians was validated in a previous study.[8] Second, we examined fatty 188 
acid composition in the serum rather than in the erythrocyte membrane phospholipids 189 
with an advantage of longer-term dietary consumption of fatty acids. A previous study, 190 
however, showed that erythrocyte membrane, compared with plasma, reflects usual 191 
dietary intakes more strongly for EPA and DHA but not for ALA[25]. Third, the sera 192 
were stored over a number of years. Our previous study showed that the 8-year 193 
repeatability of the proportion of ω-3 polyunsaturated fatty acids on serum total fat were 194 
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fairly good (12.8% vs 12.3%, p=0.14) [26]. Another study showed that 7 to 12 years’ 195 
storage did not affect the serum ALA (reliability coefficient =0.72) [27]. Moreover in 196 
the present study, the results were not altered when we excluded 114 cases and 228 197 
controls whose sera were collected before 1990 (not shown). Fourth, we did not have 198 
information on dementia type (ie, Alzheimer or vascular dementia). Instead, we had 199 
information on dementia with and without history of stroke. The associations seemed 200 
similar between dementia with and without history of stroke. Fifth, the generalizability 201 
to populations other than the Asian population should be cautious, especially for 202 
eicosapentaenoic and docosahexaenoic acids, since Japanese consume far higher fish 203 
than do non-Asians. Last, we did not survey prevalent dementia at baseline. Instead, we 204 
set the baseline at least 5 years before the beginning of the dementia survey, thereby 205 
reducing the possibility of reverse causation. 206 
 In conclusion, serum proportions of ALA were inversely associated with risk of 207 
disabling dementia among Japanese. This suggests that low ALA intake may carry a 208 
potential risk of dementia. Although the causality needs to be confirmed by randomized 209 
control trials, we identified serum α-linolenic acid as a biomarker that predicts future 210 
dementia. 211 
 212 
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Table 1. Baseline characteristics of dementia cases and non-cases, CIRCS aged 40-74 years.
Non-cases Dementia cases p  for difference
Number 630 315
Age, y 64.2 64.6 0.37
Male gender, % 34 34 1.00
Body mass index, kg/m2 24.0 23.7 0.27
Current smokers, % 19 24 0.07
Current drinkers, % 27 27 0.85
Systolic blood pressure, mmHg 133 137 0.002
Diastolic blood pressure, mmHg 78 79 0.02
Antihypertensive medication, % 31 34 0.43
Diabetes mellitus, % 5 11 0.004
Serum total cholesterol, mg/dL 199 201 0.37
Cholesterol-lowering medication, % 3 2 0.48
Saturated fatty acids, % total fatty acids 34.6 34.8 0.34
Monounsaturated fatty acids, % total fatty acids 22.4 22.7 0.13
Omega-6 polyunsaturated fatty acids, % total fatty acids 32.0 31.6 0.23
Alpha-linolenic acid, % total fatty acids 0.97 0.90 0.002
Eicosapentaenoic acid, % total fatty acids 3.63 3.55 0.57
Docosahexaenoic acid, % total fatty acids 5.50 5.53 0.82
24 
 
 
 
Q1 Q2 Q3 Q4 Trend p
0.30-0.74 0.75-0.90 0.91-1.11 1.12-2.26
Median, % total fatty acid 0.64 0.82 1.00 1.32
Number of non-cases 157 155 156 162
Number of cases 115 64 61 75
Matched OR (95%CI)* 1.0 0.56 (0.38-0.82) 0.52 (0.35-0.77) 0.60 (0.41-0.88) 0.01
Multivariable OR (95%CI)† 1.0 0.57 (0.39-0.85) 0.51 (0.34-0.76) 0.61 (0.41-0.90) 0.01
Q1 Q2 Q3 Q4 Trend p
0.50-2.14 2.15-3.23 3.24-4.66 4.67-12.8
Median, % total fatty acid 1.62 2.70 3.89 6.02
Number of non-cases 157 158 157 158
Number of cases 82 85 77 71
Matched OR (95%CI)* 1.0 1.00 (0.68-1.48) 0.90 (0.59-1.37) 0.81 (0.52-1.27) 0.32
Multivariable OR (95%CI)† 1.0 0.99 (0.67-1.49) 0.90 (0.58-1.39) 0.79 (0.49-1.26) 0.28
Q1 Q2 Q3 Q4 Trend p
1.78-4.19 4.20-5.23 5.24-6.52 6.53-11.1
Median, % total fatty acid 3.55 4.77 5.80 7.69
Number of non-cases 157 158 156 159
Number of cases 81 69 81 84
Matched OR (95%CI)* 1.0 0.86 (0.58-1.27) 1.05 (0.68-1.60) 1.10 (0.68-1.78) 0.54
Multivariable OR (95%CI)† 1.0 0.88 (0.58-1.31) 1.20 (0.77-1.86) 1.18 (0.72-1.94) 0.34
Table 2. Age and sex-matched and multivariate adjusted conditional odds ratios and 95% confidence intervals of incident dementia
according to quartiles of serum alpha-linolenic, eicosapentaenoic and docosahexaenoic acids.
Men and Women
Alpha-linolenic acid (%total fatty acid)
*Matched with age (±3 years), sex, area and baseline-year
†Multivariable model further includes age, smoking status, systolic blood pressure, diabetes mellitus and medication of hypertension.
Eicosapentaenoic acid (%total fatty acid)
Docosahexaenoic acid (%total fatty acid)
 
 
